Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.

Journal of molecular biology - 1 Jul 2005

Wu Herren, Pfarr David S, Tang Ying, An Ling-Ling, Patel Nita K, Watkins Jeffry D, Huse William D, Kiener Peter A, Young James F

Abstract excerpt

We describe here the selection of ultra-potent anti-respiratory syncytial virus (RSV) antibodies for preventing RSV infection. A large number of antibody variants derived from Synagis (palivizumab), an anti-RSV monoclonal antibody that targets RSV F protein, were generated by a directed evolution approach that allowed convenient manipulation of the binding kinetics. Palivizumab variants with about 100-fold slower...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Viral

Share to Chlorocebus aethiops

Share to Enzyme-Linked Immunosorbent Assay

Share to Neutralization Tests

Share to Respiratory Syncytial Virus Infections

Share to Respiratory Syncytial Viruses

Source

Identifiers

PMID: 15907931
DOI: 10.1016/j.jmb.2005.04.049

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.PMID 15907931Read ↗

Complete definition of how antibodies used to prevent RSV are affected by F mutationsSemantic proximity Read ↗

Molecular modeling predicts novel antibody escape mutations in respiratory syncytial virus fusion glycoproteinSemantic proximity Read ↗

Molecular Modeling Predicts Novel Antibody Escape Mutations in the Respiratory Syncytial Virus Fusion Glycoprotein.Semantic proximity Read ↗

Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogenSemantic proximity Read ↗

Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus.Semantic proximity Read ↗

Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion proteinSemantic proximity Read ↗

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.Semantic proximity Read ↗

Single-Domain Antibodies and Their Formatting to Combat Viral InfectionsSemantic proximity Read ↗

Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.Semantic proximity Read ↗

Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potencySemantic proximity Read ↗

Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.Semantic proximity Read ↗

Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.